ERBB2 and breast cancer: Trastuzumab (Herceptin), a monoclonal antibody that binds to domain IV of HER2, has an antiproliferative effect on cells overexpressing HER2 and is currently used as a treatment for breast cancer (Slamon et al., 2001).